priaxon.com
Logo

Alliances

Strategic partnerships are of particular importance for all of Priaxon's business aspects.
Priaxon is looking for collaborations with leading pharmaceutical companies concerning the partnering of the in-house drug discovery programs. The gain of expertise and capacity are essential for the successful development of promising preclinical candidates.

In addition it also important to unify different competences in an alliance from the very start of a program, addressing hard-to-drug targets.

 

Boehringer Ingelheim and Priaxon
Collaboration to research and develop novel treatments for cancer. Companies to advance mdm2/p53 inhibitors, which hold potential to address various tumor types

 

Faron and Priaxon
Collaboration to research and develop a new class of AOC3/SSAO antagonists for the treatment of cardivascular diseases.

 

Priaxon participates in "Neuroallianz" Consortium
"Neuroallianz" is a consortium consisting out of different companies with the goal to develope innovative products against different neurodegenerative diseases.
"Neuroallainz" is one of three winners of the Biopharma contest of the BMBF.

 

BioChancePLUS: Development of new kinase inhibitors
The BMBF supports a integrated program for the reaerch on new and structurally innovative kinase inhibitors. Partners in this project are Crelux and Spherotech, two companies also located in Munich

 

Bayerische Forschungsstiftung: Individualized Tumor Therapy
Together with Kinaxo and the Technical University of Munich Priaxon is supported by the Bayerische Forschungsstiftung to develope innovative and individualized tumor therapies.

 

NexusPharma, Inc., Philadelphia
This is Priaxon's competent biology partner for protein protein interactions working together with Fox Chase Cancer Center